Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function

12 de noviembre de 2026 actualizado por: University of Minnesota

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans

This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.

Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.

The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.

Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.

This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.

Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.

Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.

Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.

Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.

Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.

The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Manda Keller-Ross
  • Número de teléfono: 612-625-3175
  • Correo electrónico: kell0529@umn.edu

Copia de seguridad de contactos de estudio

  • Nombre: Emma Lee
  • Número de teléfono: 612-301-8617
  • Correo electrónico: leex4357@umn.edu

Ubicaciones de estudio

    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota - Children's Rehabilitation Center
        • Contacto:
          • Manda Keller-Ross
          • Número de teléfono: 612-625-3175
          • Correo electrónico: kell0529@umn.edu
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

45 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Female individuals, assigned female sex at birth, aged 45 to 65 years.
  • Clinician-diagnosed hypertension, either controlled or uncontrolled.
  • Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Nicotine/tobacco, probiotic, or antibiotic use within the previous six months.
  • Body mass index of 40 kg/m² or greater.
  • Use of hormonal contraceptives or systemic exogenous hormones.
  • Diagnosis of diabetes.
  • Respiratory disease other than well-controlled asthma.
  • Severe neurological conditions, including traumatic brain injury or stroke.
  • Existing endocrine abnormalities.
  • History of chemotherapy.
  • Surgery within the preceding six months.
  • Autoimmune disorders.
  • History of organ transplantation.
  • Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders.
  • Immunosuppressive or glucocorticoid therapy.
  • Chronic illnesses that preclude participation at the investigator's discretion.
  • Intermittent fasting with unwillingness or inability to complete a four-week washout period before enrollment.
  • Inability to speak, read, or understand English.
  • Inability to provide informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Panthea Core Supplementation

Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.

Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.

Otros nombres:
  • Akkermansia muciniphila-Based Probiotic
  • Panthea Core Supplementation
Comparador de placebos: Placebo

Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.

Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.

Otros nombres:
  • Placebo
  • Placebo for Panthea Core

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Muscle Sympathetic Nerve Activity (MSNA)
Periodo de tiempo: Baseline to 12 weeks

Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups.

Baseline to 12 weeks
Incidence of Adverse Events
Periodo de tiempo: From initiation of supplementation through approximately 4 weeks after the 12-week intervention

Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core.

From initiation of supplementation through approximately 4 weeks after the 12-week intervention
Change in Comprehensive Metabolic Panel Laboratory Measures
Periodo de tiempo: Baseline and 12 weeks

Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group.

Baseline and 12 weeks
Supplement Adherence
Periodo de tiempo: Throughout the 12-week intervention

Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%.

Throughout the 12-week intervention
Study Retention
Periodo de tiempo: From enrollment through completion of the 12-week intervention

Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%.

From enrollment through completion of the 12-week intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Flow-Mediated Dilation (FMD)
Periodo de tiempo: Baseline to 12 weeks

Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion.

Baseline to 12 weeks
Change in Heart Rate Variability (HRV)
Periodo de tiempo: Baseline to 12 weeks

Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings.

Baseline to 12 weeks
Change in Cardiovagal Baroreflex Sensitivity
Periodo de tiempo: Baseline to 12 weeks

Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg.

Baseline to 12 weeks
Change in Sympathetic Baroreflex Sensitivity
Periodo de tiempo: Baseline to 12 weeks

Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol.

Baseline to 12 weeks
Change in Blood Pressure
Periodo de tiempo: Baseline to 12 weeks

Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter.

Baseline to 12 weeks
Change in Menopause-Specific Quality of Life
Periodo de tiempo: Baseline to 12 weeks

Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains.

Baseline to 12 weeks
Change in Depressive Symptoms (PHQ-9)
Periodo de tiempo: Baseline to 12 weeks

Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9).

Baseline to 12 weeks
Change in Insomnia Severity (ISI)
Periodo de tiempo: Baseline to 12 weeks

Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index.

Baseline to 12 weeks
Change in Subjective Sleep Quality (PSQI)
Periodo de tiempo: Baseline to 12 weeks

(PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index.

Baseline to 12 weeks
Change in Objective Sleep Parameters
Periodo de tiempo: Baseline to 12 weeks

Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing.

Baseline to 12 weeks
Change in Cognitive Function (MoCA)
Periodo de tiempo: Baseline to 12 weeks

Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation.

Baseline to 12 weeks
Change in Gut Microbiome Composition
Periodo de tiempo: Baseline to 12 weeks

Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation.

Baseline to 12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Manda Keller-Ross, University of Minnesota

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de febrero de 2027

Finalización primaria (Estimado)

31 de enero de 2030

Finalización del estudio (Estimado)

31 de enero de 2030

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PT-2026-34798

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir